Submitted for Publication: May 9, 2011; final revision received December 7, 2011; accepted December 9, 2011.
Financial Disclosure: Dr Siegle is an unpaid consultant for Trial IQ and Neural Impact. During the past 3 years, Dr Thase reported having served as an advisor/consultant for Alkermes, AstraZeneca, Bristol-Myers Squibb Company, Eli Lilly and Company, GlaxoSmithKline, Janssen Pharmaceutica, MedAvante Inc, Merck Inc, Neuronetics Inc, Novartis Inc, Otsuka Inc, PamLab Inc, Pfizer Inc, Pharmaneuroboost Inc, Shire US Inc, Supernus Pharmaceuticals, and Wyeth Pharmaceuticals. In 2009 and 2010, Dr Thase had speakers bureau affiliations with AstraZeneca, Bristol-Myers Squibb Company, Eli Lilly and Company, Merck Inc, and Wyeth Pharmaceuticals. Dr Thase has equity holdings in MedAvante Inc; has received royalties from American Psychiatric Publishing Inc, Guilford Publications, and Herald House; and has a family relationship with senior staff at Embryon Inc (formerly Cardinal Health and Advogent). During the past 3 years, Dr Thase has received research funding from the Agency for Healthcare Research and Quality, Eli Lilly and Company, GlaxoSmithKline, the National Institute of Mental Health, Otsuka Inc, Pfizer Inc, Pharmaneuroboost, and Roche, Inc. Dr Friedman has speakers bureau or advisory board affiliations with AstraZeneca, Eli Lilly and Company, GlaxoSmithKline, and Pfizer Wyeth-Ayerst and has obtained grant/research support from Aspect Medical Systems, Indevus, AstraZeneca, Bristol-Myers Squibb, Pfizer, sanofi-aventis, Wyeth-Ayerst, Cyberonics, Novartis, NorthStar/St Jude Medical, Medtronics, and Respironics.
Funding/Support: This study was supported by grants MH074807, MH082998, MH58356, MH58397, and MH69618 from the National Institutes of Health; by the Pittsburgh Foundation; and by the Emmerling Fund.
Role of the Sponsor: The sponsors had no role in the design and conduct of the study; in the collection, analysis, and interpretation of the data; or in the preparation, review, or approval of the manuscript.
Previous Presentation: Portions of this manuscript were presented at the 2010 annual meeting of the World Congress for Behavioral and Cognitive Therapies; June 5, 2010; Boston, Massachusetts.
Online-Only Material: The eMaterials cited in the text and the eFigures, eTables, and eReferences, are available at http://www.pitt.edu/~gsiegle/Siegle-fMRI-Prediction-Archives12-AuthorMaterial.pdf.
Additional Contributions: We thank Agnes Haggerty, BS, Mauri Cesare, BA, our therapists, and the staff of the Mood Disorders Treatment and Research Program at Western Psychiatric Institute and Clinic; the intrepid community therapists who worked on the study; and our patients, without whom none of this work would have been possible.